Drug Profile
Research programme: antibacterials - iNtRON Biotechnology
Alternative Names: Bacteriophage-based antibacterials - iNtRON Biotechnology; Bio-drug therapeutics for superbacteria - iNtRON Biotechnology; N-Rephasin® NPA200; NPA 200Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator iNtRON biotechnology
- Developer iNtRON Biotechnology
- Class Antibacterials; Bacteriophages; Endolysins; Proteins
- Mechanism of Action Cell membrane modulators; Cell wall modulators; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Bacterial-infections in South Korea (Parenteral, Injection)
- 19 Nov 2018 Anti-vancomycin-resistant enterococcal and anti-tuberculosis biologics licensed to Roivant Sciences
- 19 Nov 2018 Preclinical trials in Bacterial infections in South Korea (Parenteral)